Structural Heart Disease

Patients with stable CAD who quit smoking reduced the risk of a major event by nearly 50%, while a reduction in smoking habits demonstrated minimal effects.

Nieca Goldberg, MD, discusses important news and updates in cardiovascular health among women from the early portions of 2024.

The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.

Implementation of an artificial intelligence-enabled ECG reduced the risk of all-cause mortality within 90 days among hospitalized patients.

Less than 2 months after being the subject of an FDA AdComm meeting, Abbott's TriClip TEER System has received approval for tricuspid regurgitation.

A recap of the biggest FDA news and decisions in cardiovascular medicine from the first 3 months of 2024, with commentary on recent announcements by Deepak Bhatt, MD, MPH, MBA.

The hospitalization risk was reduced to up to 75% for patients with heart disease treated with both antidepressants and psychotherapy to manage anxiety or depression symptoms.

A significant association between Lp(a) and adverse cardiovascular outcomes was altered by renal function in patients undergoing percutaneous coronary intervention.

Elevated Lp(a) may influence LDL-C levels and prevent LDL-C target achievement in patients at very high cardiovascular risk.

Our February 2024 cardiology month in review, recaps FDA news, top data from International Stroke Conference and major journals, and perspectives form a bevy of key opinion leaders in the field on hot topics and news from across the spectrum of cardiovascular medicine.

This 2024 American Heart Month 2024 feature paints a picture describing the current state of cardiology by asking what the most prevalent and important issues facing the specialty are today from the perspective of 9 leading experts.

The FDA approval of Edwards Lifesciences EVOQUE tricuspid valve replacement system for treatment of symptomatic severe tricuspid regurgitation is the first of its kind for a transcatheter therapy.

Even when cholesterol levels were only moderately elevated, familial hypercholesterolemia variants were associated with greater cardiovascular risk.

A recent statewide analysis in California found TAVR rates exceed SAVR for severe aortic stenosis, despite contradicting consensus guideline recommendations.

A real-world analysis in the United States suggests hospital volume may not be the lone predictor of outcomes in pediatric cardiac surgery.

A multidisciplinary panel assembled by the Society for Cardiovascular Angiography & Interventions examined and supported the role of intravascular ultrasounds in lower extremity revascularization procedures.

Presented at AHA 2023, new analyses of VOYAGER PAD suggest the benefit of rivaroxaban plus aspirin for high-risk and complex populations with PAD.

Elliot Elias, MD, MPH, provides perspective on recent advances in structural heart disease as well as highlighting the upcoming 40th annual Echocardiography and Structural Heart Symposium at Baptist Health.

Presented at ESC 2023, the accumulation of inactive time from childhood through young adulthood was related to heart damage, regardless of body weight and blood pressure.

Last week, the FDA authorized marketing for Viz.AI’s Viz HCM, a standalone ECG analysis software to identify adult patients for further follow-up for hypertrophic cardiomyopathy.

The FDA has announced Abiomed has initiated a recall of all left-sided Impella pumps, citing inadequate instructions for use as it pertains to precautions to take with patients who have undergone TAVR.

Days with a combination of a heat wave and high fine particulate matter air pollution may double the risk of a fatal heart attack, says new research.

The new scientific statement from the AHA indicates multiple social, economic, and health variables contribute to disparities in the development, diagnosis, and treatment of PAD.

On June 15, 2023, Bristol Myers Squibb announced the FDA approved an updated label for mavacamten (Camzyos) to reflect the agent's ability to reduce the need or eligibility for septal reduction therapy in patients with obstructive HCM based on VALOR-HCM.

An analysis of the Dubbo study suggests elevated Lp(a) is an independent and significant predictor of recurrent CHD in older people over a 16-year period.

An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.

An analysis of 2 population-based cohorts suggests coronary artery calcium scores added to traditional risk-based models showed better discrimination than polygenic risk scores for CHD risk prediction.

A posthoc analysis of the EMPEROR-Preserved trial suggested empagliflozin decreased the risk of heart failure hospitalization or cardiovascular death, regardless of background diuretic status.

With ACC 2023 in the rearview, the HCPLive editorial team compiled perspectives on the meeting’s top piece of news from half a dozen clinicians specializing in various subspecialties across the spectrum of cardiovascular care.